Report Detail

Pharma & Healthcare Global Central Nervous System (CNS) Stimulant Drugs Market Size, Status and Forecast 2019-2025

  • RnM3811759
  • |
  • 11 October, 2019
  • |
  • Global
  • |
  • 152 Pages
  • |
  • QYResearch
  • |
  • Pharma & Healthcare

Table of Contents

    1 Study Coverage

    • 1.1 Central Nervous System (CNS) Stimulant Drugs Product Introduction
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Central Nervous System (CNS) Stimulant Drugs Market Size Growth Rate by Type
      • 1.4.2 Amphetamine
      • 1.4.3 Cocaine
      • 1.4.4 Caffeine
      • 1.4.5 Others
    • 1.5 Market by Application
      • 1.5.1 Global Central Nervous System (CNS) Stimulant Drugs Market Size Growth Rate by Application
      • 1.5.2 Attention Deficit Hyperactivity Disorder (ADHD)
      • 1.5.3 Narcolepsy
      • 1.5.4 Others
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Central Nervous System (CNS) Stimulant Drugs Market Size
      • 2.1.1 Global Central Nervous System (CNS) Stimulant Drugs Revenue 2014-2025
      • 2.1.2 Global Central Nervous System (CNS) Stimulant Drugs Sales 2014-2025
    • 2.2 Central Nervous System (CNS) Stimulant Drugs Growth Rate by Regions
      • 2.2.1 Global Central Nervous System (CNS) Stimulant Drugs Sales by Regions
      • 2.2.2 Global Central Nervous System (CNS) Stimulant Drugs Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Central Nervous System (CNS) Stimulant Drugs Sales by Manufacturers
      • 3.1.1 Central Nervous System (CNS) Stimulant Drugs Sales by Manufacturers
      • 3.1.2 Central Nervous System (CNS) Stimulant Drugs Sales Market Share by Manufacturers
    • 3.2 Central Nervous System (CNS) Stimulant Drugs Revenue by Manufacturers
      • 3.2.1 Central Nervous System (CNS) Stimulant Drugs Revenue by Manufacturers (2014-2019)
      • 3.2.2 Central Nervous System (CNS) Stimulant Drugs Revenue Share by Manufacturers (2014-2019)
    • 3.3 Central Nervous System (CNS) Stimulant Drugs Price by Manufacturers
    • 3.4 Central Nervous System (CNS) Stimulant Drugs Manufacturing Base Distribution, Product Types
      • 3.4.1 Central Nervous System (CNS) Stimulant Drugs Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Central Nervous System (CNS) Stimulant Drugs Product Type
      • 3.4.3 Date of International Manufacturers Enter into Central Nervous System (CNS) Stimulant Drugs Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type

    • 4.1 Global Central Nervous System (CNS) Stimulant Drugs Sales by Type
    • 4.2 Global Central Nervous System (CNS) Stimulant Drugs Revenue by Type
    • 4.3 Central Nervous System (CNS) Stimulant Drugs Price by Type

    5 Breakdown Data by Application

    • 5.1 Overview
    • 5.2 Global Central Nervous System (CNS) Stimulant Drugs Breakdown Data by Application

    6 North America

    • 6.1 North America Central Nervous System (CNS) Stimulant Drugs by Country
      • 6.1.1 North America Central Nervous System (CNS) Stimulant Drugs Sales by Country
      • 6.1.2 North America Central Nervous System (CNS) Stimulant Drugs Revenue by Country
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Central Nervous System (CNS) Stimulant Drugs by Type
    • 6.3 North America Central Nervous System (CNS) Stimulant Drugs by Application

    7 Europe

    • 7.1 Europe Central Nervous System (CNS) Stimulant Drugs by Country
      • 7.1.1 Europe Central Nervous System (CNS) Stimulant Drugs Sales by Country
      • 7.1.2 Europe Central Nervous System (CNS) Stimulant Drugs Revenue by Country
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Central Nervous System (CNS) Stimulant Drugs by Type
    • 7.3 Europe Central Nervous System (CNS) Stimulant Drugs by Application

    8 Asia Pacific

    • 8.1 Asia Pacific Central Nervous System (CNS) Stimulant Drugs by Region
      • 8.1.1 Asia Pacific Central Nervous System (CNS) Stimulant Drugs Sales by Region
      • 8.1.2 Asia Pacific Central Nervous System (CNS) Stimulant Drugs Revenue by Region
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 South Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Thailand
      • 8.1.10 Malaysia
      • 8.1.11 Philippines
      • 8.1.12 Vietnam
    • 8.2 Asia Pacific Central Nervous System (CNS) Stimulant Drugs by Type
    • 8.3 Asia Pacific Central Nervous System (CNS) Stimulant Drugs by Application

    9 Central & South America

    • 9.1 Central & South America Central Nervous System (CNS) Stimulant Drugs by Country
      • 9.1.1 Central & South America Central Nervous System (CNS) Stimulant Drugs Sales by Country
      • 9.1.2 Central & South America Central Nervous System (CNS) Stimulant Drugs Revenue by Country
      • 9.1.3 Brazil
    • 9.2 Central & South America Central Nervous System (CNS) Stimulant Drugs by Type
    • 9.3 Central & South America Central Nervous System (CNS) Stimulant Drugs by Application

    10 Middle East and Africa

    • 10.1 Middle East and Africa Central Nervous System (CNS) Stimulant Drugs by Country
      • 10.1.1 Middle East and Africa Central Nervous System (CNS) Stimulant Drugs Sales by Country
      • 10.1.2 Middle East and Africa Central Nervous System (CNS) Stimulant Drugs Revenue by Country
      • 10.1.3 Turkey
      • 10.1.4 GCC Countries
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Central Nervous System (CNS) Stimulant Drugs by Type
    • 10.3 Middle East and Africa Central Nervous System (CNS) Stimulant Drugs by Application

    11 Company Profiles

    • 11.1 Astellas Pharma
      • 11.1.1 Astellas Pharma Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Astellas Pharma Central Nervous System (CNS) Stimulant Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Astellas Pharma Central Nervous System (CNS) Stimulant Drugs Products Offered
      • 11.1.5 Astellas Pharma Recent Development
    • 11.2 Biogen
      • 11.2.1 Biogen Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Biogen Central Nervous System (CNS) Stimulant Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Biogen Central Nervous System (CNS) Stimulant Drugs Products Offered
      • 11.2.5 Biogen Recent Development
    • 11.3 Celltech
      • 11.3.1 Celltech Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Celltech Central Nervous System (CNS) Stimulant Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Celltech Central Nervous System (CNS) Stimulant Drugs Products Offered
      • 11.3.5 Celltech Recent Development
    • 11.4 Eli Lilly and Company
      • 11.4.1 Eli Lilly and Company Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Eli Lilly and Company Central Nervous System (CNS) Stimulant Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Eli Lilly and Company Central Nervous System (CNS) Stimulant Drugs Products Offered
      • 11.4.5 Eli Lilly and Company Recent Development
    • 11.5 GlaxoSmithKline
      • 11.5.1 GlaxoSmithKline Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 GlaxoSmithKline Central Nervous System (CNS) Stimulant Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 GlaxoSmithKline Central Nervous System (CNS) Stimulant Drugs Products Offered
      • 11.5.5 GlaxoSmithKline Recent Development
    • 11.6 Johnson and Johnson
      • 11.6.1 Johnson and Johnson Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 Johnson and Johnson Central Nervous System (CNS) Stimulant Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 Johnson and Johnson Central Nervous System (CNS) Stimulant Drugs Products Offered
      • 11.6.5 Johnson and Johnson Recent Development
    • 11.7 Merck
      • 11.7.1 Merck Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 Merck Central Nervous System (CNS) Stimulant Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 Merck Central Nervous System (CNS) Stimulant Drugs Products Offered
      • 11.7.5 Merck Recent Development
    • 11.8 Novartis
      • 11.8.1 Novartis Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 Novartis Central Nervous System (CNS) Stimulant Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 Novartis Central Nervous System (CNS) Stimulant Drugs Products Offered
      • 11.8.5 Novartis Recent Development
    • 11.9 Perdue Pharma
      • 11.9.1 Perdue Pharma Company Details
      • 11.9.2 Company Business Overview
      • 11.9.3 Perdue Pharma Central Nervous System (CNS) Stimulant Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.9.4 Perdue Pharma Central Nervous System (CNS) Stimulant Drugs Products Offered
      • 11.9.5 Perdue Pharma Recent Development
    • 11.10 Pfizer
      • 11.10.1 Pfizer Company Details
      • 11.10.2 Company Business Overview
      • 11.10.3 Pfizer Central Nervous System (CNS) Stimulant Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.10.4 Pfizer Central Nervous System (CNS) Stimulant Drugs Products Offered
      • 11.10.5 Pfizer Recent Development
    • 11.11 Roche
    • 11.12 Sanofi
    • 11.13 Shire
    • 11.14 Takeda Pharmaceuticals
    • 11.15 Thermo Fisher Scientific

    12 Future Forecast

    • 12.1 Central Nervous System (CNS) Stimulant Drugs Market Forecast by Regions
      • 12.1.1 Global Central Nervous System (CNS) Stimulant Drugs Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Central Nervous System (CNS) Stimulant Drugs Revenue Forecast by Regions 2019-2025
    • 12.2 Central Nervous System (CNS) Stimulant Drugs Market Forecast by Type
      • 12.2.1 Global Central Nervous System (CNS) Stimulant Drugs Sales Forecast by Type 2019-2025
      • 12.2.2 Global Central Nervous System (CNS) Stimulant Drugs Revenue Forecast by Type 2019-2025
    • 12.3 Central Nervous System (CNS) Stimulant Drugs Market Forecast by Application
    • 12.4 North America Central Nervous System (CNS) Stimulant Drugs Forecast
    • 12.5 Europe Central Nervous System (CNS) Stimulant Drugs Forecast
    • 12.6 Asia Pacific Central Nervous System (CNS) Stimulant Drugs Forecast
    • 12.7 Central & South America Central Nervous System (CNS) Stimulant Drugs Forecast
    • 12.8 Middle East and Africa Central Nervous System (CNS) Stimulant Drugs Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Central Nervous System (CNS) Stimulant Drugs Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      This report studies the global market size of Central Nervous System (CNS) Stimulant Drugs in key regions like North America, Europe, China and Japan, focuses on the consumption of Central Nervous System (CNS) Stimulant Drugs in these regions.
      This research report categorizes the global Central Nervous System (CNS) Stimulant Drugs market by top players/brands, region, type and end user. This report also studies the global Central Nervous System (CNS) Stimulant Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      Astellas Pharma
      Biogen
      Celltech
      Eli Lilly and Company
      GlaxoSmithKline
      Johnson and Johnson
      Merck
      Novartis
      Perdue Pharma
      Pfizer
      Roche
      Sanofi
      Shire
      Takeda Pharmaceuticals
      Thermo Fisher Scientific

      Central Nervous System (CNS) Stimulant Drugs market size by Type
      Amphetamine
      Cocaine
      Caffeine
      Others

      Central Nervous System (CNS) Stimulant Drugs market size by Applications
      Attention Deficit Hyperactivity Disorder (ADHD)
      Narcolepsy
      Others

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Europe
      Germany
      France
      UK
      Italy
      Russia
      Asia-Pacific
      China
      Japan
      South Korea
      India
      Australia
      Indonesia
      Thailand
      Malaysia
      Philippines
      Vietnam
      Central & South America
      Brazil
      Middle East & Africa
      Turkey
      GCC Countries
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Central Nervous System (CNS) Stimulant Drugs market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Central Nervous System (CNS) Stimulant Drugs market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Central Nervous System (CNS) Stimulant Drugs companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Central Nervous System (CNS) Stimulant Drugs submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Central Nervous System (CNS) Stimulant Drugs are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (MT). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Central Nervous System (CNS) Stimulant Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.


      Summary:
      Get latest Market Research Reports on Central Nervous System (CNS) Stimulant Drugs. Industry analysis & Market Report on Central Nervous System (CNS) Stimulant Drugs is a syndicated market report, published as Global Central Nervous System (CNS) Stimulant Drugs Market Size, Status and Forecast 2019-2025. It is complete Research Study and Industry Analysis of Central Nervous System (CNS) Stimulant Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

      Last updated on

      REPORT YOU MIGHT BE INTERESTED

      Purchase this Report

      $3,900.00
      $5,850.00
      $7,800.00
      2,963.52
      4,445.27
      5,927.03
      3,520.36
      5,280.54
      7,040.72
      423,727.20
      635,590.80
      847,454.40
      276,684.72
      415,027.08
      553,369.44
      Credit card Logo

      Related Reports


      Reason to Buy

      Request for Sample of this report